CE & Events
- This event has passed.
Pharmacy Compounding Symposium
Event Navigation
LEADING HEALTH LAW FIRM HANCOCK DANIEL HOSTS PHARMACY COMPOUNDING SYMPOSIUM
Hancock Daniel joins VCU and Virginia Bio for an Inaugural Pharmacy Compounding Symposium in November
This Inaugural Pharmacy Compounding Symposium will be held on Friday, November 30, 2018, with a Welcome Reception and Pharmacy Tour kicking off the event on Thursday, November 29, 2018. Virginia Commonwealth University, as well as Virginia Bio will join Hancock Daniel to bring together regulators and industry leaders at the federal and state level to discuss emerging legal and regulatory trends in pharmacy compounding. Among other topics, discussions will include the topics of recent FDA Guidance and USP <795>, <797> and <800> and where the co-regulatory scheme conflicts.
Attendance at the event (including CE credit) is free of charge. Content will be relevant to anyone involved in pharmacy compounding operations (e.g., hospital, community, retail, home infusion, long-term care, specialty), including pharmacy owners and managers, compounding technicians, and in-house counsel. The symposium will be conducted in compliance with the Accreditation Council for Pharmacy Education (ACPE) criteria for planning and implementation. Space is limited and those who plan to attend should register by November 5th, 2018 by sending an e-mail to wwhite@hancockdaniel.com.
“Current market drivers including improved life expectancy and increasing drug shortages are anticipated to further accelerate the growth of the pharmacy compounding market,” says Mary Malone, a founding partner at Hancock Daniel. “Today, there are a record number of compounding pharmacies that supply customized drugs to patients whose needs are not met by commercially available drugs. This is a highly regulated industry at both the state and federal level and navigating those sometimes-divergent regulatory landscapes can be tricky.”
Elizabeth Whalley Buono, Director at Hancock Daniel says, “We are optimistic that this symposium will provide the most up-to-date information about a broad array of important issues including how the FDA is working with state partners to assure that they are able to address the risks that may be presented by compounded drugs. We anticipate informative dialogue among this region’s leaders in compounding practice, regulation, and counsel, and we are very pleased that we have received conditional approval from the APCE to be able to offer continuing education credits for the attendees.”
From transactional and regulatory matters to litigation and lobbying assistance, Hancock Daniel is the advocate, thought partner and trusted advisor to the healthcare industry.
